Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
10 September 2022 - 12:32AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the research and
discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that its Chief Executive
Officer, Dr. Tiago Reis Marques, will deliver a virtual
presentation at the H.C. Wainwright 24th Annual Global Investment
Conference, being held from September 12-14, 2022 in New York, as
follows:
Date: Monday, September 12, 2022 Time: 7:00AM ET
During the conference Pasithea will be
participating in virtual 1x1 meetings that can be requested via
H.C. Wainwright.
A pre-recorded presentation will be made will be
accessible via the Company’s website at ir.pasithea.com.
About Pasithea Therapeutics
Corp. Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Pasithea Therapeutics Corp. Company
Contact Dr. Tiago Reis Marques Chief Executive
Officer E: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations Lisa M. Wilson In-Site Communications,
Inc. T: 212-452-2793 E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Historical Stock Chart
From Jul 2023 to Jul 2024